Prof Salomon Manier speaks to ecancer about the IMROZ frailty subgroup analysis at IMS 2024.

In the phase 3 IMROZ study in transplant-ineligible newly diagnosed multiple myeloma patients, isatuximab in combination with bortezomib, lenalidomide, and dexamethasone significantly improved progression-free survival and induced deep and sustained responses.

In this post-hoc subgroup analysis of IMROZ the efficacy of this regimen was tested across frail and non-frail subgroups.

Frailty scores at baseline were calculated based on age, modified Charlson Comorbidity Index calculated using medical history at baseline, and Eastern Cooperative Oncology Group performance status. Patients with a frailty score of 2 or higher were considered frail.

The results indicate the positive effects of isatuximab, bortezomib, lenalidomide, and dexamethasone in frail patients.

Prof Manier concludes by addressing the clinical implications of these findings.